A plan to fight back against antibiotic resistance, developed by an international consortium managed by Swiss researchers, calls for marketing incentives for research and development investments into crucial new drugs. Researchers and public health organisations have long been raising awareness about the problem of antibiotic-resistant bacteria, and the lack of new treatments being developed to combat these strains. Now, DRIVE-AB, an international consortium of public health organisations, researchers and pharmaceutical companies piloted by the University of Geneva (UNIGE) and England-based AstraZeneca, has published a report that proposes concrete economic solutions to combat this global problem. + Only use antibiotics if necessary, officials warn + In ten years, Swiss agriculture reduces antibiotics usage by half + Swiss fight drug-resistant bacteria on many fronts In particular, the writers of the report, published Wednesday, recommend a market entry reward for antibiotics ...
